Redx Pharma Plc

Redx Pharma's CSO Richard Armer outlines development ambitions and clinical targets

Redx Pharma Plc's (LON:REDX) chief scientific officer Richard Armer sat down with Proactive London's Andrew Scott to discuss the opportunities ahead for their cancer and fibrosis portfolios.

Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

Quick facts: Redx Pharma Plc

Price: £0.10

Market: AIM
Market Cap: £12.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...



Full interview: Redx Pharma gets green light to increase dose in lead cancer...

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug. It comes after the firm successfully navigated the first part of its early-stage trial for RXC004. The asset's part...

4 days, 17 hours ago

2 min read